TABLE 2.
Hamster heart graft survival in LEW recipients treated with combination treatment with FK506a
| Group | Drug combined with FK506 |
Dose (mg/kg/ day) |
Duration (days) |
n | Survival (days) | Median survival (days) |
|---|---|---|---|---|---|---|
| 1 | BQR | 3.0 | −1 → 30 | 6 | 4, 5, 5, 5, 7, >100 | 5.0 |
| 2 | BQR | 4.0 × 3 → 3.0 | −1 → 13 | 5 | >100, >100, >100, >100, >100 | >100 |
| 3 | BQR | 4.0 × 3 → 3.0 | −1 → 30 | 6 | 89, >100, >100, >100, >100, >100 | >100 |
| 4b | BQR | 4.0 × 3 → 3.0 | −1 → 30 | 6 | 5, 22, 24, >100, >100, >100 | >62.0 |
| 5 | BQR | 4.5 | −1 → 30 | 4 | 3,c 9,c >75, >75 | >42.0 |
| 6 | RS-61443 | 10 | −1 → 30 | 6 | 4, 5, 5, 5, >100, >100 | 5.0 |
| 7 | RS-61443 | 20 | −1 → 13 | 6 | 19, >78, >78, >78, >90, >90 | >78.0 |
| 8 | RS-61443 | 20 | −1 → 30 | 6 | >100, >100, >100, >100, >100, >100 | >100.0 |
| 9 | RS-61443 | 30 | −1 → 30 | 6 | >91, >91, >100, >100, >100, >100 | >100.0 |
| 10 | RS-61443 | 40 | −1 → 30 | 6 | >78, >92,d >92,d >92, >100, >100 | >92.0 |
| 11 | Cyclophosphamide | 5 | −1 → 30 | 5 | 5, 5, 5, 5, 6 | 5.0 |
| 12 | Cyclophosphamide | 7.5 | −1 → 7 | 5 | >35, >35, >35, >35, >35 | >35.0 |
| 13 | Cyclophosphamide | 7.5 | −1 → 13 | 5 | >49, >49, >49, >50, >50 | >49.0 |
| 14 | Cyclophosphamide | 7.5 | −1 → 30 | 5 | >64, >64, >64, >64, >64 | >64.0 |
| 15 | Cyclophosphamide | 10 | −1 → 13 | 6 | >50, >60, >63, >63, >64, >64 | >63.0 |
| 16 | Cyclophosphamide | 15 | −1 → 9 | 4 | 29, >43, >47, >47 | >45.0 |
| 17 | Methotrexate | 1.0 | −1 → 13 | 3 | 7,c 7,c 9c | 7.0 |
| 18 | Methotrexate | 1.0 | −1 → 5 | 3 | 9, c 10, c >40 | 10.0 |
| 19 | Methotrexate | 1.0 | −1 → 3 | 7 | 8, 10, 10, >19, >19, >49, >49 | >19.0 |
| 20 | Methotrexate | 1.0 | −1 → 1 | 2 | 8, 9 | 8.5 |
| 21 | Methotrexate | 0.5 | −1 → 9 | 4 | 10,c 13,c 43, >49 | 28.0 |
| 22 | Methotrexate | 0.25 | −1 → 13 | 3 | 4, 4, 6 | 4.0 |
| 23 | Mizoribine | 5.0 | −1 → 30 | 3 | 5, 5, 7 | 5.0 |
| 24 | Mizoribine | 7.5 × 3 → 5.0 | −1 → 30 | 6 | 3,c 5, 5, >77, >77, >100 | >41.0 |
| 25 | Azathioprine | 15 | −1 → 30 | 2 | 4, 5 | 4.5 |
| 26 | Azathioprine | 45 | −1 → 30 | 3 | 5, 5, 23c | 5.0 |
| 27 | Azathioprine | 60 | −1 → 30 | 4 | 5, 8,c 17,c 19c | 12.5 |
| 28 | DSPG | 2.5 | −1 → 30 | 4 | 4, 5, 5, 5 | 5.0 |
| 29 | DSPG | 5.0 × 3 → 2.5 | −1 → 30 | 6 | 23, 38, >70, >70, >70, >76 | >70.0 |
| 30 | DSPG | 5.0 | −1 → 30 | 4 | 9, 24,c 32,c >76 | 28.0 |
| 31 | Cyclophosphamide | 80.0 | −10 | 5 | >71, >71, >71, >79, >79 | >71.0 |
| (i.p.) |
a
FK506 was administered intramuscularly at a dose of 2.0 mg/kg/day for the first 6 days (days 0 to 5), then 1.0 mg/kg/day (days 6 to 30) and continued at 0.5 mg/kg/day every other day (days 31 to 100).
b
FK506 was used at 1.0 mg/kg/day for the first 30 days (0 to 30) and continued at 0.5 mg/kg/day every other day (days 31 to 100).
c
Animal died with functioning graft.
d
RS-61443 treatment was discontinued 25 days after transplantation because of the appearance of diarrhea and body weight loss.